<DOC>
	<DOCNO>NCT00004101</DOCNO>
	<brief_summary>Phase I trial study effectiveness monoclonal antibody therapy treat patient recurrent non-Hodgkin 's lymphoma . Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Recurrent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess safety tolerability monoclonal antibody Hu1D10 patient previously treat non-Hodgkin 's lymphoma express antigen recognize Hu1D10 . II . Determine maximum tolerate dose monoclonal antibody Hu1D10 patient . III . Evaluate pharmacokinetics , compare pharmacology different dose level , determine optimal biological dose drug patient . IV . Evaluate antilymphoma effect drug patient . OUTLINE : This dose escalation , multicenter study . Patients receive monoclonal antibody Hu1D10 IV 2-4 hour day 1 , 8 , 15 , 22 . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos monoclonal antibody Hu1D10 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 6 patient experience dose limit toxicity . Once MTD determine , additional cohort 3-6 patient receive Hu1D10 IV 2-4 hour day 1-5 . Patients follow 4 week , 50 day , periodically thereafter disease progression .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma relapse refractory prior treatment At least 50 % malignant cell biopsy specimen reactive 1D10 antibody OR least 50 % B cell within tumor reactive 1D10 extensive T cell infiltration present Measurable evaluable disease Circulating tumor cell few 5,000/mm3 ( dose escalation phase ) Not eligible curative conventional therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Platelet count least 75,000/mm3 Bilirubin less 2.5 mg/dL SGOT le 3 time upper limit normal Creatinine le 2.0 mg/dL No New York Heart Association class III IV heart disease No clinically significant pulmonary disease No active serious infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : At least 4 week since prior interferon Concurrent transfusion allow At least 4 week since prior cytotoxic chemotherapy No concurrent antineoplastic agent At least 4 week since prior corticosteroid No concurrent glucocorticoid At least 4 week since prior radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>